Drug development firm SkyePharma said expectations for 2012 pre-exceptional operating profit remain unchanged and is confident of future trading as it launches its asthma treatment product flutiform across Europe. [15 Oct '12]
Infrastructure India, an AIM-listed investment group, pleased its investors with a 50.2 per cent leap in its net asset value (NAV) to 207.3m pounds over the year ended March. The value of the company's investments rose 94.9 per cent to 216.7m pounds, while the NAV per share climbed from 92p to 95p. The company's Chairman said the period was one of "significant operating progress" in what has been a challenging period for investing in Indian infrastructure and stressed that it [23 Aug '12]
The resources investment firm Creon Resources is to raise 12.1m pounds from an open offer, with around 2.4bn shares up for sale at 0.5p per share, a 1.5p discount to the share price at the close yesterday. Jeswant Natarajan, Chief Executive Officer of Creon, commented: 'Today's announcement...is extremely positive news for Creon given its difficult historic trading performance since its inception, and provides the directors with a number of possibilities in executing its inve [22 Jun '12]
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.